Zeneca's Casodex diarrhea incidence 50% lower than Eulexin in prostate cancer therapy -- ASCO.
Executive Summary
ZENECA CASODEX DIARRHEA INCIDENCE 50% LESS THAN EULEXIN in treatment of prostate cancer patients, according to results of a study reported by Nicholas Vogelzang, MD, University of Chicago, May 23 at the American Society of Clinical Oncology annual meeting in Los Angeles. The incidence of diarrhea was 10% in the Casodex (bicalutamide) group compared to 24% in the group treated with Schering-Plough's Eulexin (flutamide), leading to 43% fewer withdrawals from therapy in patients treated with Casodex.